GeneDx (WGS) – Investment Analysts’ Recent Ratings Changes

GeneDx (NASDAQ: WGS) recently received a number of ratings updates from brokerages and research firms:

  • 11/18/2026 – GeneDx had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.
  • 11/16/2026 – GeneDx was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 11/10/2026 – GeneDx had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock, down from $90.00.
  • 11/2/2026 – GeneDx had its “sell (d)” rating reaffirmed by Weiss Ratings.
  • 10/9/2026 – GeneDx was downgraded by Zacks Research from “strong-buy” to “hold”.
  • 10/1/2026 – GeneDx had its price target raised by Guggenheim from $74.00 to $83.00. They now have a “buy” rating on the stock.

GeneDx Price Performance

NASDAQ:WGS traded up $4.67 during trading hours on Wednesday, reaching $51.96. The company had a trading volume of 1,710,385 shares, compared to its average volume of 948,984. The company has a quick ratio of 3.85, a current ratio of 4.16 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average of $72.36 and a two-hundred day moving average of $69.72. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The firm has a market capitalization of $1.56 billion, a PE ratio of -13.75 and a beta of 2.00.

GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.21. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. The company had revenue of $123.10 million during the quarter, compared to analysts’ expectations of $122.93 million. During the same period last year, the business earned ($0.27) earnings per share. Analysts forecast that GeneDx Holdings Corp. will post -0.41 earnings per share for the current year.

Insider Activity

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the sale, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the completion of the transaction, the chief financial officer directly owned 44,945 shares in the company, valued at $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,206 shares of company stock valued at $1,808,056 over the last three months. 25.17% of the stock is currently owned by insiders.

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

Featured Stories

Receive News & Ratings for GeneDx Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.